Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics
ACXP Price/Volume Stats
| Current price | $2.90 | 52-week high | $4.85 |
| Prev. close | $2.90 | 52-week low | $2.33 |
| Day low | $2.81 | Volume | 5,700 |
| Day high | $2.91 | Avg. volume | 30,779 |
| 50-day MA | $3.11 | Dividend yield | N/A |
| 200-day MA | $3.40 | Market Cap | 33.85M |
ACXP Stock Price Chart Interactive Chart >
Acurx Pharmaceuticals, Inc. (ACXP) Company Bio
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Latest ACXP News From Around the Web
Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct OfferingAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,333,333 shares of its common stock (or pre-funded warrants in lieu thereof) at a combined effective purchase price of $3.00 per share (or pre-funded warrant) in a registered direc |
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business UpdateAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2023. |
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business UpdateAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2023 financial results on Friday, May 12, 2023, at 8:00 am ET before the U.S. financial markets open. |
Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
New to The Street Announces its Corporate Interviews, Episodes 459 and 460 With the TV Shows Airings to Start on Saturday, April 22, 2023, at 3:30 PM ETNew to The Street Announces its Corporate Interviews, Episodes 459 and 460 Featuring the following:1).Acurx Pharmaceuticals, Inc.'(NASDAQ: ACXP) ($ACXP) 2).SMX (Security Matters), PLC.'s (NASDAQ: SMX) ($SMX).3). Linqto's 4). Hapbee Technologies, Inc. (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) 5).Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). 6).The Sustainable Green Team, Ltd. (OTCQX: SGTM) ($SGTM) Business TV show on 3-major Networks. NEW YORK, April 21, 2023 (GL |
ACXP Price Returns
| 1-mo | -5.23% |
| 3-mo | -14.45% |
| 6-mo | -21.62% |
| 1-year | 7.41% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.14% |
| 2022 | -7.90% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...